Trials / Completed
CompletedNCT02583477
Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years – 130 Years
- Healthy volunteers
- Not accepted
Summary
A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations (with chemotherapy or AZD5069) in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
Detailed description
This is a Phase Ib and II open-label, multi-center study to evaluate the safety, tolerability, pharmacodynamics, and antitumor activity of MEDI4736 in combination with chemotherapy or AZD5069 in patients with pancreatic ductal adenocarcinoma (PDAC). This study will consist of 2 independent cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MEDI4736 in combination with nab-paclitaxel and gemcitabine | MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion |
| DRUG | MEDI4736 in combination with AZD5069 | MEDI4736 via IV infusion and oral AZD5069 |
Timeline
- Start date
- 2016-03-25
- Primary completion
- 2018-07-09
- Completion
- 2018-07-09
- First posted
- 2015-10-22
- Last updated
- 2019-08-14
- Results posted
- 2019-08-14
Locations
7 sites across 2 countries: United States, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02583477. Inclusion in this directory is not an endorsement.